MLS on the verge of breaking above that 31p high of April 2002. This was the item that triggered the current breakout last week:

LONDON (AFX) - Medical Solutions PLC, the cancer and pathology services
group, said The Doctors Laboratory, the leading provider of private cervical
screening in the UK, has stated that they are adopting Medical Solutions'
SurePath for their LBC screening.
The SurePath system will be supplied by Medical Solutions in the UK under
licence from TriPath Imaging Inc.
Medical Solutions chief executive Charles Green said the group now awaits
the NICE (the National Institute of Clinical Excellence) report issuing their
final guidance to the NHS, after their preliminary report recommended the use of
liquid based cytology within the NHS. This report is expected in September.
newsdesk@afxnews.com
slm/

See impressive bb comment here since then and on various BBs.

Interims due mid-Sept.
Ahead of a long weekend there might yet be some profit-taking, but with results and statements to come within the next 2-3 weeks I would guess most who are planning to do so will reduce rather than exit, and the effect will be perhaps be outweighed by new buyers waking up to what's happening.

MLS don't have the field to themselves with the nhs - there are still other contenders in the running. But it's looking hopeful in my opinion.

Company website

External Shareholders at 21 Aug 03:
89.15m 2p Ords - Edinburgh Fund Mgrs PLC 6.32%, INVESCO Asset Mgmt Ltd 5.78%, Prudential PLC 5.61%, Cantor Fitzgerald Europe 5.34%, Texas Group PLC 4.12%, Singer & Friedlander Inv 3.45%, Other Dirs 1.65%.

jzl

Juzzle, nice to see this on the move - I bought these back in 2000 @50p, watched them triple, sold half and still own the rest. They seem to have reinvented themselves of late and with interims due shortly + a positive news flow, things are looking good.

BTW another old "tech" period share I hold is SUN which is also on the rise (no pun intended) - nearly back to 50% of what I paid for them.

RNS Number:0738P
Medical Solutions PLC
27 August 2003

27 August 2003



Medical Solutions plc

Medical Solutions plc, the cancer and pathology services group, advises that its
interim results for the six months to 30 June 2003 will be announced on
Wednesday 17th September 2003.

An analyst briefing will be held in the Dome Room, No 1 Cornhill on the morning
of the announcement at 9.30am.

For further information please contact:

Ann-marie Wilkinson/Mike Wort, Beattie Financial 0207 398 3300

Resumption of the uptrend on news today.



RNS Number:2619P
Medical Solutions PLC
02 September 2003


Immediate Release 2 September 2003


MEDICAL SOLUTIONS plc

BOARD STRENGTHENED


Medical Solutions plc ("the Company" or "Medical"), the cancer and pathology
services group, today announces the following appointments to the Board. These
changes take immediate effect

Professor Karol Sikora (53), currently a Non-Executive Director of Medical, is
appointed to the Executive Board as Chief Scientific Director. Professor Sikora
joined Medical in April 2002, prior to which he held a number of senior research
positions within the pharmaceutical industry. These posts included: Vice
President of Global Clinical Research (Oncology) at Pharmacia Corporation;
Deputy Director of Clinical Research for the Imperial Cancer Research Fund;
Chief of the World Health Organisation and Clinical Director for Cancer Services
at Hammersmith Hospital, London.

Currently Professor Sikora is a Consultant to AstraZeneca; Special Adviser to
HCA Healthcare, the leading provider of healthcare services in America; Visiting
Professor of Cancer Medicine and honorary Consultant Oncologist at Imperial
College School of Medicine, Hammersmith Hospital, London.

Medical Solutions today also announces a second appointment - that of Dr Sue
Foden (50) who joins Medical as a Non-Executive Director. Dr Foden has
significant experience in the healthcare market having been Chief Executive of
Cancer Research Campaign Technology Limited (1987-2000) and Cancer Research
Ventures Limited (1998-2000).

Dr Foden is currently a Venture Partner of Merlin Biosciences Limited, the
specialist life science investor trust. As part of this role Dr Foden is a
Director of Ardana Bioscience Limited; BioVex Limited; De Novo Pharmaceuticals
Limited and PIramed Limited (all of whom Merlin Bioscience have an active
investment in).

Personally Dr Foden is a Director of the Institute of Cancer Research, Royal
Cancer Hospital, London; Cascade Fund Management Limited; NESTech Fund
Management Limited and Oxford Ancestors Limited, and is a member of the Wellcome
Trust's Technology Transfer Strategy Panel.

Commenting on the appointments, Charles Green, Chief Executive of Medical
Solutions said,

"We are delighted to announce these two appointments today, both of which add
significant weight to our management team. Professor Sikora has already proved
a great asset to the Board in his role as a Non-Executive and I am delighted
that he has decided to become a full-time member of the team.

I am also delighted that Dr Sue Foden has agreed to join Medical. She has
immense experience and knowledge in the biotechnology and pharmaceutical markets
and I very much look forward to working with Sue in driving Medical forward."


For further information, please contact:

Medical Solutions
Charles Green, Chief Executive Officer Tel: +44 (0) 115 973 9010
Andy Longstaffe, Finance Director

Beattie Financial Tel: +44 (0) 20 7398 3300
Mike Wort/ Ann-marie Wilkinson


Notes to Editors:

Medical Solutions plc provides world leading services and technology for cancer
diagnosis and pathology, supporting the Healthcare, Pharmaceutical and
Biotechnology sectors.

The group has two major divisions. The Services Division has a range of services
including Specialist Pathology, Biomaterials Resources and Expertise, and 5
Laboratories. These services are provided to the Pharma/Botech Industry
worldwide and to Healthcare providers, both public and private. The Technology
Divisions' range includes specialist imaging software for telemedicine, image
analysis and quantitation, and the SurePath liquid based cytology (smear test)
system. This division is also key in supporting its' Service divisions offerings
to both the Drug Development market and the Healthcare market.

The combination of world-renowned expertise, state of the art reference
laboratory facilities and innovative imaging technology puts Medical in a unique
position.


This information is provided by RNS
The company news service from the London Stock Exchange
END

LONDON (AFX) - Medical Solutions PLC, the supplier of services for drug
developers and healthcare providers, said it bought a second laboratory in
Dubai, the Histopathology & Specialty Laboratory (HSL), for 275,000 stg in
shares and cash.
A further 75,000 stg in cash is payable depending on the lab achieving
certain agreed financial targets.
In June Medical Solutions bought its first laboratory in Dubai, establishing
the company as a significant provider of speciality healthcare services in the
region.
The company said HSL will provide additional histopathology capacity
complementing its existing laboratory in Dubai.
newsdesk@afxnews.com
ak/

RNS Number:8475P
Medical Solutions PLC
17 September 2003

17 September 2003



MEDICAL SOLUTIONS

INTERIM RESULTS FOR THE PERIOD TO 30 JUNE 2003



Financial Highlights


* Turnover (on continuing operations) increases three fold to #2.9m
(2002: #1m)
* Profit after tax #0.5m (2002: #0.4m loss)
* Gross margin increased to 63% from 49%
* Continued investment in new services


Operational Highlights


* Consolidation of activities at Nottingham
* Widened services to support drug development - first contracts now in place
* NICE approval of Liquid Based Cytology (LBC) for Cervical Cancer Screening
in UK
* Acquisition of histopathology laboratory in London:
- Provides entry into private market
* Joint venture with Sonic for Cytology and LBC
* Acquisition of two private laboratories in Dubai, rapidly becoming a
centre of excellence for private healthcare services to the region
* Board strengthened with the appointment of Prof Karol Sikora to an
executive role on the board and the appointment of Dr Sue Foden as a non
executive director


Commenting the Chairman, Sir Gareth Roberts, said:

"Medical Solutions has transformed into a highly focused business specialising
in laboratory diagnosis and pathology for healthcare providers and support
services for drug developers. This has been a significant period of growth for
the company with turnover on continuing operations increasing threefold and the
completion of a number of key acquisitions.

We have a clear focus, and the necessary infrastructure and strategic alliances,
skills and technology to build a substantial and very profitable business."


For further information, please contact:
Medical Solutions
Charles Green, CEO Tel: +44 (0) 207 398 3300 (today only)
Andy Longstaffe, FD +44 (0) 115 973 9010


Beattie Financial
Mike Wort/Ann-marie Wilkinson Tel: +44 (0) 207 398 3300/07730 415019



Introduction

Medical Solutions has transformed into a highly focused business specialising in
laboratory diagnosis and pathology for healthcare providers and support services
for drug developers. During the first six months of 2003 we have taken several
key steps in achieving our vision of developing the new Nottingham facility into
an international centre of excellence. The combination of world-renowned
expertise, state of the art reference laboratory facilities and innovative image
analysis and quantitation technology puts Medical Solutions in a unique position
to fully exploit the increasing demand for outsourced support services.

The Group's business is divided into two main areas:

The Services Division delivers a range of services including specialist
pathology, biomaterials resources and expertise coupled with a number of its own
laboratory facilities. These services are provided to the global pharmaceutical
and biotechnology Industry as well as public and private healthcare providers.
Through creating new support services for drug development we are able to
develop new technologies and create a pipeline of products and services which we
can offer to our healthcare customers.

The Technology Division has a range of products, which includes specialist
software in telemedicine and imaging, and includes SurePath, our system for
preparing Liquid Based Cytology smear samples.

Operational Highlights

Key to the development and delivery of our range of services is the
consolidation of all activities at the new freehold premises on the new business
park in Nottingham. The building consists of 22,000sq metre of office and
laboratory space with room for expansion. The facilities will be fully
compliant with the requirements of IS9002, Clinical Pathology Accreditation
(CPA) and current Good Laboratory Practice (GLP) regulations. We have already
relocated our imaging businesses from Liverpool and Tunbridge Wells, and will be
moving our existing laboratories in Nottingham to the new site within the next 5
months.

During the period we have secured significant contracts with major
pharmaceutical companies and anticipate repeat orders of increasing magnitude as
they build up confidence in our capabilities. We have an expanding order book,
currently #2.3million, and order pipeline of some #4.5m with several individual
tenders valued over #1million.

In May we established an operation in Research Triangle Park(RTP), North
Carolina, USA, headed up by Dr Mark Browne, the founder of Kinetic Imaging to
meet the demand, centered around RTP, for expert analysis using our imaging
products to support drug discovery.

On 26 June 2003 we acquired a private laboratory in Dubai with annual post tax
profits of approximately #1million, and have established the company as a
provider and partner in Dubai Healthcare City (DHCC), the planned $2 billion
green-field development currently being constructed. The aim of the Dubai
Healthcare City initiative is to provide the highest quality healthcare services
through the creation of a world class cluster of healthcare professionals and
service providers to satisfy the needs of the expanding private hospital market
in Dubai, the Gulf, and its catchment area of 2 billion people in the region.
Other significant healthcare providers involved in the DHCC initiative include
The Harvard Medical School, The Johns Hopkins Medical Institute and The Mayo
Clinic. We are now well positioned to fulfil the laboratory needs, histopathogy
expertise and telepathology of this exciting new opportunity, in addition to
supporting its' public health systems.

On 14th August 2003 NICE (National Institute of Clinical Excellence) approved
Liquid Based Cytology for Cervical Cancer Screening in the UK. SurePath is one
of only two Food & Drug Agency approved Liquid Based Cytology smear test systems
which have been trialled by the NHS and reviewed by NICE, for implementation in
the UK. There are currently 4.7 million smear tests performed each year in
England and Wales. The continued delay of the announcement from the Department
of Health has caused great disappointment to the Company and this will impact
the full year performance. However, the Company believes that a full
contribution will come from SurePath in 2004.

On 4 July 2003 we acquired a private histopathology laboratory in London and
formed a joint venture with Sonic Healthcare, the listed Australian company, to
provide histopathology and cytology service in London and in the private
healthcare market outside London. This acquisition is also an important step in
creating the conduit through which we intend to offer LBC services to UK
healthcare providers.

Financial Overview

Turnover in this period from continuing operations trebled to #2.9 million (2002
#1.0 million), split as to #1.8 million (2002 #0.4million) from Services and
#1.1 million (2002 #0.6million) from Technology. Our order book is expanding
with contracts from a number of major pharmaceutical companies, and several
tenders worth in excess of #1million.

The Group's gross margin from continuing operations grew from 49% to 63%,
primarily due to the impact of the new business areas - reference laboratories,
drug development and private healthcare which attract significantly higher
margins than our historical business.

The operating loss from continuing operations was #1.07 million (2002 #1.08
million) including central costs. The gains in gross margin generated have been
offset by the investment in the expanded infrastructure built for our drug
development services in anticipation of the increased size of contracts and
order book.

Profit after tax for the period was #0.5 million (2002 #0.4million loss), helped
by the release of #1.5 million of the December 2002 provision for tax of #2.1
million, which related mainly to the disposal of Adams Healthcare.

At 30 June we had #4.4 million cash available. During the period we spent #4.3
million on capital expenditure including #3.7million on the freehold premises
in Nottingham, with the remainder on laboratory equipment. We acquired the
Welcare laboratory in Dubai for #7 million cash with #0.7million of costs. This
acquisition was partly financed by the issue of #2million worth of new ordinary
shares to the vendor with the remainder in cash. Deferred consideration of #3
million has been recognised in long-term creditors as we expect the laboratory
to exceed the warranted post tax profits of #0.95million for each of the first
three years under our ownership. During the period we also repaid the #2.4m
outstanding on Adams Healthcare debt, and assumed #4million of new debt. Cash
outflow from operations was #1.5 million in the period however #0.5 million
related to increased debtors as a result of sales made just prior to 30 June,
which have now been collected.

Board Changes

Dr Ian Ellis was appointed to the main Board as Medical Director in March. He
has been instrumental in the development of PathLore, our pathology diagnosis
business.

We were also delighted to appoint Professor Karol Sikora as Scientific Director,
who will have particular responsibility for leading our Drug Development
Services. Karol joined the group as a Non-Executive Director in April 2002. On
Karol's appointment as an Executive Director, we announced the appointment of Dr
Sue Foden as Non-Executive Director. Dr Foden has immense experience and
knowledge in the Biotechnology and Pharmaceutical markets having been Chief
Executive of Cancer Research Campaign Technology Limited (1987-2000) and Cancer
Research Ventures Limited (1998-2000). Dr Foden is currently a Venture Partner
of Merlin Biosciences Limited, the specialist life science investor trust.

Prospects

There remains a global shortage of pathologists, an increasing requirement for
specialist laboratories, a need for new technology and automation in pathology
and an expanding market for Private Healthcare. The support services we can now
offer in Drug Development represent a unique combination of services and
technologies which allows us to aid drug target identification, design and run
clinical trials, develop tests, and utilise those tests in expanding our service
offering for healthcare providers.

Our revenue streams are tangible and clear, and now include Dubai, the UK
private healthcare market, SurePath Liquid Based Cytology, and rapidly expanding
orders for our Drug Development services. We have the cash to finance the
business through to a cash generative position, and make positive additions to
our portfolio of skills and technologies.

We are now well positioned to deliver expectations in the forthcoming years as
the prospects of rapidly increasing our revenues are tangible. We have a clear
focus, and the necessary infrastructure and strategic alliances, skills and
technology to build a substantial and very profitable business.

Sir Gareth Roberts FRS, FREng
Non-Executive Chairman

Looking intersting again over the last couple of days - a break above 39 would be nice.

Cleared the busy area around 39p yesterday and a small tick up today - still long and chart shows much fresh air above this level.

what other update news from MLS?

Sold half my holding this morning for +50% which was nice.

RNS Number:1624R
Medical Solutions PLC
22 October 2003





October 22, 2003



Medical Solutions announces Department of Health decision on

Liquid Based Cytology





Medical Solutions (LSE: MLS), the cancer diagnostics company, announces that the
Department of Health has today accepted the decision by NICE that a new cervical
screening system - Liquid Based Cytology ("LBC") will replace the current
cervical smear test in England and Wales.



Medical Solutions will supply its SurePath LBC system, which has been used for
the NICE (National Institute of Clinical Excellence) pilot study. The
excellent results the SurePath LBC System obtained in the NICE pilot for both
cancer detection and reduction in inadequate tests has greatly contributed to
the decision by DOH to adopt the NICE guidance on LBC in England and Wales.



The SurePath LBC system is more effective than conventional smear tests in
picking up likely cancer cases and US studies have demonstrated a 64.4%
improvement over conventional methods in the detection of high grade
abnormalities. The system introduced by SurePath is automated thereby reducing
any operator errors and increasing the efficiency of the new LBC test. Early
detection of such abnormalities greatly increases the chances of effective
treatment.



LBC is also a significant step towards the introduction of even more powerful
detection tools in the future including automatic imaging and molecular markers.
The SurePath LBC system already has some of these systems approved in the US and
trials are underway in the UK.



Charles Green CEO of Medical Solutions said



"We are delighted by the Department of Health's adoption of LBC in England and
Wales. The Medical Solutions Surepath LBC system is one of only two FDA
approved products and our unique technologies will ensure greatly improved
collection and screening of the four million smears performed every year."



Contact:



Medical Solutions
Charles Green, Chief Executive Officer Tel: +44 (0) 115 973 9010

anymoe good news? look like this share worth to hold from now on....

GREAT NEWS FOR YOU/SHAREHOLDERS
Up 8.50 / 17.99 per cent @ 4,736,092 million volume
I forget the www I found it.
................................
More info:
www.moneyextra.com/stocks/LSE/MLS---------Click company news.

Plenty of favourable press coverage this weekend so far. Some profit-taking was to be expected yesterday at the end of such a positive week, but the share price soaked up those sells with ease.

Analysts and brokers newly alerted to this stock by the nhs and related government statement should be coming up with upgrades soon. Plus the possibility of it becoming a very tasty takeover target now that it looks like taking a fair chunk of that nhs business. Not that it is reliant on the LBC cervical cancer testing work. It has several solid divisions (expect some newsflow from those between now and end of year).

Sonic (Australian Top-100 company) has an active connection with MLS on several fronts and is considered by many to be a likely bidder at some stage.

jzl

Some more on Sonic - lifted from an excellent piece by S-H-B on another BB:

..Sonic is the largest medical diagnostics Company in Australasia and New Zealand, providing quality Pathology and radiology services in the community.

...has made rapid progress and turnover is now almost 1billion AUS dollars.

Sonic Stategy:
Capture synergies with Sonic pathology
Build relationships with independent healthcare entities
Acquisitions
UK pathology opportunities
European pathology

Sonic Statement:
The group’s UK operation, TDL, continues to perform strongly, with significant growth in both revenue and EBITA. Recent developments in the UK include the acquisition of the Omnilabs pathology group in July 2003 and the announcement of a strategic joint venture with the University College London Hospital (UCLH), one of the UK’s most prestigious teaching hospitals. TDL (including the merged Omnilabs operation), is expected to move into a new, state-of-the-art laboratory facility in December 2003 and will partner with UCLH to form a high-volume automated laboratory in the new facility for the routine pathology testing of both entities.

Dr Goldschmidt said that the UCLH joint venture represented an important milestone in Sonic’s history. “We are privileged to work with UCLH and we anticipate that the relationship will bring benefits to both groups at many levels. The TDL/UCLH joint venture will create the platform for growth in both the public and private pathology markets in the UK"


As above, Sonic are very very keen to gain a major foothold in the NHS, and be part of the NHS Pathology modernisation plan this has been achieved with having contracts with the NHS through TDL, and now having very close ties with MLS who are firmly established throughout the NHS, this puts Sonic now in the position as a 'stalking horse' waiting for the opportune moment to make their move on MLS.

Karol Sikora is an advisor for Astra Zeneca and does work for HCA a large US Healthcare company, But Sonic are purely a diagnostics company who have a foothold in the UK market and with Medicals business operations would be an ideal synergistic fit for Sonic.

Detailed info about Sonic and Company stategies can be found on this link
http://www.sonichealthcare.com/sonic/internet/html_corporate/index.html

2004 saw Medical Solution go from Greatness to Weakness, yet here there are no comments - - -

This stock has got to be a one way bet, it'll go back up as fast as it fell as soon as some news is out. Any thoughts on this one's future

20 times as many buys as sells today, and previous days. Something big is coming soon

snaylor

Clearly, the placing has gone well. My information is that the new board members have been well received. The city has clearly backed them in seeing off the hostile bid. Thus it is seen that the company should recover. I doubt whether there has been time for any trading improvement. Rather, the fall was overdone.

Eric

Fascinated at the lack of comment on this bb. Positive news out to day with Surepath sales. Successful fundraising behind them. Strong new board members on board. Focussing on getting the finances in order. What is more: Evil Knievel has a LONG position in MLS. Anyone with inside view of the market?

Eric

Another post to repeat the question of the last one to keep it on top page. I will go on doing this until I get an answer! Can anyone tell me what this company is worth?

Eric